Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 30 | Vintage Vibes

3 Biotech Stocks Revolutionizing Healthcare

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and transformative partnerships. To capitalize on this trend, consider adding Amgen (AMGN), BioNTech (BNTX), and Gilead Sciences (GILD), which could boost your portfolio.

StockNews.com · Feb 10, 2025

Is a new painkiller too good to be true?

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids

Salon · Feb 10, 2025

AstraZeneca, Whitehall, and a failed £450m deal for the next generation in vaccines. What went wrong?

When the pharma firm cancelled plans for a major expansion of its Merseyside plant last month, there was no shortage of questions – or blame – over responsibility

The Guardian - UK · Feb 8, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Stock Rises After Profit, Outlook Top Expectations

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.

Kiplinger · Feb 6, 2025

AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site

Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision.

The Independent UK · Feb 6, 2025

Is Harmony Biosciences Holdings Inc. (HRMY) a Biotech Stock to Consider?

Harmony Biosciences’ (HRMY) recently released growth plans and pipeline advancements have showcased the company’s dedication towards being a top contender in the highly contested biotech market. So, should investors looking to capitalize on the industry’s prospects consider investing in HRMY? Read more….

StockNews.com · Feb 6, 2025

AstraZeneca ‘very disappointed’ over axed £450m Liverpool vaccine project

As drugmaker reports 38% jump in profits, CEO denies tension with UK government after Speke plant decision

The Guardian - UK · Feb 6, 2025

Read news from The Economist, FT, and more,
with one subscription

Drug firm GSK delivers a syringe full of crowd-pleasers

Pharmaceuticals company’s higher dividend, upgrade to revenues and share buyback suggest its drugs pipeline is flowing nicely

The Guardian - UK · Feb 5, 2025

Novo Nordisk confident despite Trump tariff risk as sales of weight-loss jab soar

Europe’s biggest firm, whose sales of Wegovy almost doubled, feels it can ‘meet demands’ of US administration

The Guardian - UK · Feb 5, 2025

AstraZeneca’s U-turn on £450m Speke expansion ‘deeply disappointing’, says minister

Chris Bryant says reduction of government support was linked to change in drugmaker’s proposed investment

The Guardian - UK · Feb 3, 2025

AstraZeneca’s £450m Speke U-turn looks terrible for a pro-growth government

It seems bizarre that ministers and UK’s largest company cannot complete investment in vital life sciences sector

The Guardian - UK · Feb 3, 2025

AstraZeneca axes £450m vaccine plant in Liverpool, blaming state funding cut

Days after Rachel Reeves highlighted life sciences as UK strength, firm decides against site expansion

The Guardian - UK · Jan 31, 2025

Suspected drug deaths in Scotland down by 10 per cent, latest figures show

Suspected drugs deaths have fallen by 10 per cent in the latest quarterly data, with drug-related attendances at A&E seeing a similar decrease.

The National (Scotland) · Jan 28, 2025

Vivek Ramaswamy To Run For Ohio Governor In 2026

Vivek Ramaswamy, with support from JD Vance's team, gears up for the 2026 Ohio gubernatorial race in a competitive GOP landscape.

Wegovy maker Novo Nordisk rebuked by watchdog over failure to disclose payments to UK health groups

Danish drug giant found to have failed to accurately report spending even after admitting to errors

Kiplinger · Jan 24, 2025

Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.

The Independent UK · Jan 23, 2025

Sackler family to pay $6.5 billion for their role in ‘fueling’ opioid epidemic which has killed hundreds of thousands

Sackler family, who owned pharmaceutical company Purdue Pharma, will no longer be in control of the company or permitted to sell opioids if the new settlement plan is approved

The Independent UK · Jan 23, 2025

Purdue Pharma and owners to pay $7.4 billion in settlement to lawsuits over the toll of OxyContin

Members of the Sackler family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion to settle lawsuits over the toll of the powerful prescription painkiller

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times · Jan 23, 2025

Sacklers, Purdue To Pay $7.4 Bn Over Opioid Crisis

Several US states have reached a $7.4 billion settlement with the Sackler family and their pharmaceutical company Purdue over the opioid crisis that has ravaged the lives of millions of Americans, officials said Thursday.

The Guardian - US · Jan 23, 2025

Purdue Pharma and Sacklers reach new $7.4bn settlement over opioids crisis

Settlement resolves thousands of lawsuits alleging Oxycontin caused addiction crisis

International Business Times UK · Jan 22, 2025

'It's Out of Control': UnitedHealth Group and Peers Charged Americans 1000% More for Drugs

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

Kiplinger · Jan 17, 2025

Medicare Price Negotiations To Continue Under the Trump Administration

The Centers for Medicare & Medicaid Services plans to negotiate the prices for 15 new drugs, although it says its seeking "greater transparency" in price talks.

Latin Times · Jan 16, 2025

UnitedHealth Is Price Gouging Cancer Patients by Overcharging 'Thousands of Percent' for Live-Saving Meds, Pocketing Extra Billions: Feds

The UnitedHealth Group is overcharging patients for necessary life-saving drugs as a result of price gouging that increases the cost of such medication exponentially.

StockNews.com · Jan 15, 2025

3 Niche Biotech Stocks Redefining Innovation

The biotech market offers great investment potential due to innovative advancements in genetic profiling, biologics, CRISPR technology, and rare disease treatments driving strong demand and growth. Therefore, investing in strong biotech stocks like Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), and United Therapeutics (UTHR) could be wise. Read on.

The Guardian - UK · Jan 15, 2025

At last, Britain has a legal drug consumption room – thanks to one man’s civil disobedience

Former heroin addict Peter Krykant set up a safe consumption van during Covid, at great personal cost. But his sacrifice paved the way for real change, says Birkbeck’s Kojo Koram

1 … 29 30 31 32

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.